Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 3 | Journal for ImmunoTherapy of Cancer

Fig. 3

From: Novel TLR2-binding adjuvant induces enhanced T cell responses and tumor eradication

Fig. 3

Modulation of intratumoral lymphoid and myeloid compartment by AV-SLPHPV conjugate. Mice were vaccinated ten days after s.c. TC-1 tumor challenge and sacrificed on day 9 after vaccination to analyze tumor-infiltrated lymphocytes and myeloid populations. (a) Percentages of CD4+ T cells, CD8+ T cells (of live cells; 7-AAD) and Db-RAHYNIVTF+ (HPV16 E7-specific) CD8+ T cells in tumor tissue as determined by flow cytometry. One outlier removed from group Pam-SLPHPV in plot of tetramer (TM)+ CD8+ T cells after performance of Grubb’s test. (b) Percentages of described myeloid subpopulations within CD3CD11b+ gated live cells from tumor tissue. (c) Expression of CD11c on described myeloid subpopulations. Significance determined by unpaired t-test: ** p < 0.01

Back to article page